Literature DB >> 20159254

Voluntarily reported unintentional injections from epinephrine auto-injectors.

F Estelle R Simons1, Eric S Edwards, Edward J Read, Sunday Clark, Erica L Liebelt.   

Abstract

BACKGROUND: Epinephrine auto-injectors provide life-saving prehospital treatment for individuals experiencing anaphylaxis in community settings.
OBJECTIVE: To determine the number, demographics, and associated circumstances and outcomes of unintentional injections from epinephrine auto-injectors.
METHODS: We searched the databases of the American Association of Poison Control Centers and the Food and Drug Administration's Safety Information and Adverse Event Report System for these incidents as reported by members of the public and by health care professionals.
RESULTS: From 1994 to 2007, a total of 15,190 unintentional injections from epinephrine auto-injectors were reported to US Poison Control Centers, 60% of them from 2003 to 2007. Those unintentionally injected had a median age of 14 years (interquartile range, 8-35), 55% were female, and 85% were injected in a home or other residence. Management was documented in only 4101 cases (27%), of whom 53% were observed without intervention, 29% were treated, 13% were neither held for observation nor treated, and 4% refused treatment. In contrast, from 1969 to 2007, only 105 unintentional injections from epinephrine auto-injectors were reported to MedWatch. Forty percent of these occurred during attempts to treat allergic reactions. Injuries resulting in permanent sequelae were rarely reported to either US Poison Control Centers or to MedWatch.
CONCLUSION: The number of reported unintentional injections from epinephrine auto-injectors increased annually from 1994 to 2007. To prevent these unintentional injections, improved epinephrine auto-injector design is needed, along with increased vigilance in training the trainers and in training and coaching the users, as well as efforts to increase public awareness of the role of epinephrine auto-injectors in the first-aid treatment of anaphylaxis in the community. Copyright 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20159254     DOI: 10.1016/j.jaci.2009.10.056

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  17 in total

1.  Knowledge of allergies and performance in epinephrine auto-injector use: a controlled intervention in preschool teachers.

Authors:  Henriette Karoline Dumeier; Luca Anne Richter; Martina Patrizia Neininger; Freerk Prenzel; Wieland Kiess; Astrid Bertsche; Thilo Bertsche
Journal:  Eur J Pediatr       Date:  2018-01-31       Impact factor: 3.183

2.  A case of suicide by self-injection of adrenaline.

Authors:  Cristian Palmiere; Fabien Bévalot; Daniel Malicier; Eric Grouzmann; Tony Fracasso; Laurent Fanton
Journal:  Forensic Sci Med Pathol       Date:  2015-08-02       Impact factor: 2.007

3.  World allergy organization guidelines for the assessment and management of anaphylaxis.

Authors:  F Estelle R Simons; Ledit R F Ardusso; M Beatrice Bilò; Yehia M El-Gamal; Dennis K Ledford; Johannes Ring; Mario Sanchez-Borges; Gian Enrico Senna; Aziz Sheikh; Bernard Y Thong
Journal:  World Allergy Organ J       Date:  2011-02-23       Impact factor: 4.084

4.  Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler.

Authors:  C Breuer; B Wachall; K Gerbeth; M Abdel-Tawab; U Fuhr
Journal:  Eur J Clin Pharmacol       Date:  2013-01-05       Impact factor: 2.953

Review 5.  Anaphylaxis in children: current understanding and key issues in diagnosis and treatment.

Authors:  Chitra Dinakar
Journal:  Curr Allergy Asthma Rep       Date:  2012-12       Impact factor: 4.806

6.  Demonstration of epinephrine autoinjectors (EpiPen and Anapen) by pharmacists in a randomised, simulated patient assessment: acceptable, but room for improvement.

Authors:  Sandra M Salter; Richard Loh; Frank M Sanfilippo; Rhonda M Clifford
Journal:  Allergy Asthma Clin Immunol       Date:  2014-09-19       Impact factor: 3.406

7.  Patients' ability to treat anaphylaxis using adrenaline autoinjectors: a randomized controlled trial.

Authors:  T Umasunthar; A Procktor; M Hodes; J G Smith; C Gore; H E Cox; T Marrs; H Hanna; K Phillips; C Pinto; P J Turner; J O Warner; R J Boyle
Journal:  Allergy       Date:  2015-04-16       Impact factor: 13.146

Review 8.  Adrenaline auto-injectors for the treatment of anaphylaxis with and without cardiovascular collapse in the community.

Authors:  Aziz Sheikh; F Estelle R Simons; Victoria Barbour; Allison Worth
Journal:  Cochrane Database Syst Rev       Date:  2012-08-15

9. 

Authors:  Sarah Edgerley; Rongbo Zhu; Samira Jeimy
Journal:  CMAJ       Date:  2021-07-19       Impact factor: 8.262

10.  Pharmacists' response to anaphylaxis in the community (PRAC): a randomised, simulated patient study of pharmacist practice.

Authors:  Sandra M Salter; Brock Delfante; Sarah de Klerk; Frank M Sanfilippo; Rhonda M Clifford
Journal:  BMJ Open       Date:  2014-07-09       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.